Crystalys Therapeutics

Q: What is Crystalys Therapeutics's official website?

Crystalys Therapeutics's official website is www.crystalystx.com

Q: What is Crystalys Therapeutics's Revenue?

Crystalys Therapeutics's revenue is <$5 Million

Q: What is Crystalys Therapeutics's SIC code?

Crystalys Therapeutics's SIC: 28,283

Q: What is Crystalys Therapeutics's NAICS code?

Crystalys Therapeutics's NAICS: 32,325

Q: How many employees does Crystalys Therapeutics have?

Crystalys Therapeutics has 11-50 employees

Q: What industry does Crystalys Therapeutics belong to?

Crystalys Therapeutics is in the industry of: Manufacturing , Pharmaceuticals , Business Services

Q: What technology does Crystalys Therapeutics use?

Some of the popular technologies that Crystalys Therapeutics uses are: Microsoft 365, Microsoft PowerPoint

Q: Who is the CFO of Crystalys Therapeutics?

Crystalys Therapeutics's CFO is Justin Thacker

Q: What does Crystalys Therapeutics do?

Based in San Diego, California, Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more... effective options for people living with gout. The company's lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, Philippines and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is advancing dotinurad in global Phase 3 trials toward regulatory approval and commercial launch. Read More

Q: What are Crystalys Therapeutics social media links?

Crystalys Therapeutics Linkedin page Crystalys Therapeutics Twitter page

Manufacturing · California, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

12544 High Bluff Dr Ste 310, San Diego, ...

Website

www.crystalystx.com

Revenue

<$5 Million

Industry

Manufacturing

Pharmaceuticals

Business Services

Research & Development

ZI Rank: 1

Signal Type

Feb

Mar

Apr

May

Jun

Jul

ZI Rank

About Crystalys Therapeutics

Based in San Diego, California, Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. The company's lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, Philippines and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is advancing dotinurad in global Phase 3 trials toward regulatory approval and commercial launch.Explore more

Is this data correct?

View contact profiles from Crystalys Therapeutics

Popular SearchesCrystalys Therapeutics IncSIC Code 28,283NAICS Code 32,325Show more

Crystalys Therapeutics Org Chart

Phone

Justin Thacker

Chief Financial Officer

Phone

Get the full picture

Is Crystalys Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Earning: See what the market has to say on Crystalys Therapeutics recently announced quarterly report

Crystalys Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic

Website visits: Recent activity has been detected on your website

Congratulate Masked Content for being promoted to Masked Content at Crystalys Therapeutics

Product Launch: Get notified when Crystalys Therapeutics launches new products

Funding: Get notified immidiatlly once Crystalys Therapeutics has new funding data

Check out if Crystalys Therapeutics is spiking on competitors!

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Check if Crystalys Therapeutics has recently received funding, and reach out quickly before it becomes old news!

Click to see if Crystalys Therapeutics had a recent Job posting/layoffs

Recommended Actions

Introduce yourself to Masked Content, who has shown a strong intent to purchase lately

Find 3 more new buyers

View Email Formats for Crystalys Therapeutics

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Crystalys Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Crystalys Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Crystalys Therapeutics.

Crystalys Therapeutics financials insights

Gather financial insights about Crystalys Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2025

Series A

$205M

2026

Series B

$130M

See All Crystalys Therapeutics's Financials Insights

Crystalys Therapeutics Tech Stack

A closer look at the technologies used by Crystalys Therapeutics

See more technologies

Most Recent Scoops

Funding

Crystalys Therapeutics has secured $130 million in Series B funding. Investors included Frazier Life Sciences Management, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Pivotal Bioventure Partners, Novo Holdings, SR One, Catalys Pacific, Lightstone Ventures, Pontifax, Longwood Fund, Alexandria Venture Investments, and Wedbush Healthcare Partners.

Funding

Project

Crystalys Therapeutics is sponsoring an interventional clinical trial focused on phase 2 trial of dotinurad in XOI intolerant/uricase failure gout participants. The trial began on May 2026 with the expected completion date of August 2027. The trial is currently recruiting participants.

Laboratory Operations, Medical Research, Clinical Operations

Project

Crystalys Therapeutics is sponsoring an interventional clinical trial focused on dotinurad versus allopurinol for tophaceous gout. The trial began on August 2025 with the expected completion date of December 2027. The trial is currently in phase three.

Laboratory Operations, Medical Research, Clinical Operations

Project

Crystalys Therapeutics is sponsoring an interventional clinical trial focused on dotinurad versus allopurinol for gout. The trial began on August 2025 with the expected completion date of November 2027. The trial is currently in phase three.

Laboratory Operations, Medical Research, Clinical Operations

Project

Laboratory Operations, Medical Research, Clinical Operations

See more scoops

Top Manufacturing Companies

Frequently Asked Questions Regarding Crystalys Therapeutics

What is Crystalys Therapeutics's official website?

Crystalys Therapeutics's official website is www.crystalystx.com

What is Crystalys Therapeutics's Revenue?

Crystalys Therapeutics's revenue is <$5 Million

What is Crystalys Therapeutics's SIC code?

Crystalys Therapeutics's SIC: 28,283

What is Crystalys Therapeutics's NAICS code?

Crystalys Therapeutics's NAICS: 32,325

How many employees does Crystalys Therapeutics have?

Crystalys Therapeutics has 11-50 employees

What industry does Crystalys Therapeutics belong to?

Crystalys Therapeutics is in the industry of: Manufacturing, Pharmaceuticals, Business Services

What technology does Crystalys Therapeutics use?

Some of the popular technologies that Crystalys Therapeutics uses are: Microsoft 365, Microsoft PowerPoint

Who is the CFO of Crystalys Therapeutics?

Crystalys Therapeutics's CFO is Justin Thacker

What does Crystalys Therapeutics do?

What are Crystalys Therapeutics social media links?

Crystalys Therapeutics Linkedin page Crystalys Therapeutics Twitter page

Who invested in Crystalys Therapeutics?

Crystalys Therapeutics has 20 investors including Novo Holdings, Catalys Pacific, KB Investment & Securities and Alexandria Venture Investments LLC Alexandria Venture Investments.

Is Crystalys Therapeutics a public company?

Crystalys Therapeutics is private company therefore does not currently have an official ticker symbol

See more information about Crystalys Therapeutics

Crystalys Therapeutics Latest Hires and Their Positions

Crystalys Therapeutics is expanding and recently hired new employees. Here are the latest additions to the team.

Justin Thacker

Chief Financial Officer

Joined Nov 1, 2025

Phone

Alison McGregor

Vice President, Regulatory Affairs

Joined Nov 1, 2025

Phone

Rachel Peterson

Vice President, Clinical Development

Joined Nov 1, 2025

Phone

Sell Smarter. Win Faster.

Level up your game to ZoomInfo Copilot, intuitive AI that turns your data and high-quality ZoomInfo data into an unfair advantage for your go-to-market teams.